2nd Quarter - Report

MEHLMAN CONSULTING, INC. for BIOGEN IDEC INC.

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans Pacific Partnership (TPP) trade agreement.

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

Corporate tax reform, Patent Box, and territorial tax system.

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

Health care reform implementation issues; follow on biologics. Prescription drug user fee reauthorization and FDA reform. H.R. 5651, The Food and Drug Administration Reform Act of 2012. S. 3187, The Food and Drug Administration Safety and Innovation Act.

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 3187 (112th), H.R. 5651 (112th)

Medicare/Medicaid MMM

Health reform implementation issues. Independent Payment Advisory Board. Medicare Part D Rebate. Part B Reimbursement.

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.